Overview
Derm Brief: Practical Tips on Managing AD and Psoriasis
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this multi-media eNewsletter, Dr. Steven R. Feldman discusses challenges in diagnosing and treating atopic dermatitis and psoriasis, while reviewing current and emerging treatments, and discussing the importance of shared decision making. A patient perspective is also included, highlighting their journey and the complexities of disease management and quality of life.
This activity is intended for dermatologists, allergists, nurse practitioners, physician assistants, and other healthcare providers who treat patients with skin conditions.
The diversity and heterogeneity of atopic dermatitis and psoriasis complicate their assessment and management. During this interview, expert faculty will provide practical guidance to help increase awareness of the latest clinical outcomes data in order to optimize treatment of these inflammatory and autoimmune skin conditions.
Upon completion of this activity, participants will be able to:
• Review the patient burdens of psoriasis and atopic dermatitis
• Summarize key clinical challenges and unmet needs in the management of psoriasis and atopic dermatitis
• Compare and contrast the MOA, efficacy and safety, and onset of clinical outcomes of novel and emerging therapies for psoriasis and atopic dermatitis
• Review the patient burdens of psoriasis and atopic dermatitis
• Summarize key clinical challenges and unmet needs in the management of psoriasis and atopic dermatitis
• Compare and contrast the MOA, efficacy and safety, and onset of clinical outcomes of novel and emerging therapies for psoriasis and atopic dermatitis
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Steven R. Feldman, MD, PhD
Professor
Dermatology, Pathology, and Social Sciences & Heath Policy
Wake Forest School of Medicine
Winston-Salem, North Carolina
Professor
Dermatology, Pathology, and Social Sciences & Heath Policy
Wake Forest School of Medicine
Winston-Salem, North Carolina
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Steven R. Feldman, MD, PhD (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Celgene, Galderma Laboratories, L.P., Janssen, Lilly USA, Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron, Sanofi, Sun Pharma, Ortho Dermatology
Consultant: Abbvie, Alvotech, Amgen, Celgene, Galderma Laboratories, L.P., Janssen, Kikaku, Leo Pharma Inc., Lilly USA, Merck & Co., Mylan, Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, Ortho Dermatology, Zenoport
Speakers' Bureau: Abbvie, Amgen, Celgene, Janssen, Leo Pharma Inc., Lilly USA, Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron, Sanofi, Sun Pharma, Taro Pharmaceutical Industries Ltd., Ortho Dermatology
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Therapies under investigation for atopic dermatitis and psoriasis.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.